During the last session, Zura Bio Ltd (NASDAQ:ZURA)’s traded shares were 0.27 million, with the beta value of the company hitting 0.13. At the end of the trading day, the stock’s price was $1.23, reflecting an intraday gain of 6.96% or $0.08. The 52-week high for the ZURA share is $6.35, that puts it down -416.26 from that peak though still a striking 21.14% gain since the share price plummeted to a 52-week low of $0.97. The company’s market capitalization is $84.10M, and the average intraday trading volume over the past 10 days was 0.43 million shares, and the average trade volume was 374.36K shares over the past three months.
Zura Bio Ltd (ZURA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.29. ZURA has a Sell rating from 0 analyst(s) out of 11 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 8 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Zura Bio Ltd (NASDAQ:ZURA) trade information
Zura Bio Ltd (ZURA) registered a 6.96% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.96% in intraday trading to $1.23, hitting a weekly high. The stock’s 5-day price performance is 9.82%, and it has moved by -13.38% in 30 days. Based on these gigs, the overall price performance for the year is -59.54%. The short interest in Zura Bio Ltd (NASDAQ:ZURA) is 5.37 million shares and it means that shorts have 19.78 day(s) to cover.
The consensus price target of analysts on Wall Street is $9, which implies an increase of 86.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $15 respectively. As a result, ZURA is trading at a discount of -1119.51% off the target high and -143.9% off the low.
While earnings are projected to return -12.38% in 2025, the next five years will return -15.63% per annum.
ZURA Dividends
Zura Bio Ltd is due to release its next quarterly earnings on 2025-Mar-24. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Zura Bio Ltd (NASDAQ:ZURA)’s Major holders
Zura Bio Ltd insiders own 27.51% of total outstanding shares while institutional holders control 59.95%, with the float percentage being 82.70%. VR ADVISER, LLC is the largest shareholder of the company, while 107.0 institutions own stock in it. As of 2024-06-30, the company held over 6.02 million shares (or 8.0365% of all shares), a total value of $21.08 million in shares.
The next largest institutional holding, with 4.86 million shares, is of SUVRETTA CAPITAL MANAGEMENT, LLC’s that is approximately 6.4858% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $17.01 million.
